Clinical trials: Interstitial Pulmonary Fibrosis
Interstitial Lung Diseases, Idiopathic Pulmonary Fibrosis
A Study of the Natural Progression of Interstitial Lung Disease (ILD)
We propose to acquire data and blood samples on all patients being cared for by the Interstitial Lung Disease (ILD) program. Additionally, we will collect data and blood samples from a control group for comparator purposes.
- Conditions
- Interstitial Lung Diseases, Idiopathic Pulmonary Fibrosis, Sarcoidosis, Connective Tissue Disorder
- Trial name
- NCT00470327
- Where
- United States
- Volunteers
- 4,000 people, healthy volunteers welcome
- Sponsor
- University of Chicago
Fibrosing Interstitial Lung Diseases, Idiopathic Pulmonary Fibrosis
Yoga in Patients With Fibrosing Interstitial Lung Diseases
Fibrosing interstitial lung diseases are characterized by loss of lung function, which leads to a decrease in quality of life and physical capacity.
- Trial name
- NCT03979703
- Testing
- 12 week yoga class
- Where
- Germany
- Volunteers
- 17 people
- Sponsor
- Heidelberg University
Idiopathic Pulmonary Fibrosis (IPF)
A Trial of AGMB-447 in Participants With Idiopathic Pulmonary Fibrosis
The main goal of this clinical trial is to find out if an experimental inhaled drug, AGMB-447, can help improve lung function in people living with a lung disease called idiopathic pulmonary fibrosis (IPF).
- Trial name
- NCT07862634
- Testing
- AGMB-447
- Volunteers
- 120 people
- Sponsor
- Agomab Spain S.L.U.
Idiopathic Pulmonary Fibrosis
Safety and Tolerability Study of Macitentan in Patients With Idiopathic Pulmonary Fibrosis
The MUSIC OL study is an open-label extension study, in which all eligible patients having completed the double-blind AC-055B201/MUSIC study as scheduled receive macitentan 10 mg once daily.
- Trial name
- MUSIC OL (NCT01346930)
- Testing
- Macitentan
- Sponsor
- Actelion
Idiopathic Pulmonary Fibrosis
Chart Review Study to Describe the Clinical Profile of Idiopathic Pulmonary Fibrosis (IPF) Patients Treated With Nintedanib (OFEV®) in Real-world Practice in Spain
The present study has been designed to characterize IPF patients treated with nintedanib (OFEV®), at time of treatment initiation, with respect to their clinical profile based on real-world data from January 2016 in Spanish…
- Trial name
- NCT03281200
- Testing
- L - Antineoplastic and immunomodulating agents, L01 - Antineoplastic agents, L01X - Other antineoplastic agents
- Where
- Spain
- Volunteers
- 172 people
- Sponsor
- Boehringer Ingelheim
Lung Disease, Pulmonary Fibrosis
A Randomized, Double-Blind, Three-Arm, Phase 3b Study Comparing the Safety and Efficacy of Interferon Gamma-1b With Azathioprine, and Azathioprine Alone in Patients With IPF Receiving Prednisone
Study GIPF-003 is a Phase 3b study designed to define better therapeutic use of IFN-gamma 1b in patients wtih IPF. The study will be conducted primarily in Europe and will enroll 210 patients.
- Trial name
- NCT00052039
- Testing
- interferon-gamma 1b, azathioprine
- Where
- Italy
- Sponsor
- InterMune
Idiopathic Pulmonary Fibrosis, Cough
Efficacy and Safety of ME-015 (Suplatast Tosilate) in Cough Related to Idiopathic Pulmonary Fibrosis (COSMIC-IPF)
Orally administered ME-015 (Suplatast Tosilate) has been available on the market as a prescription drug for allergy-related conditions in Japan since 1995 with a good safety and tolerability profile.
- Conditions
- Idiopathic Pulmonary Fibrosis, Cough, IPF, Fibrotic Lung Disease
- Trial name
- COSMIC-IPF (NCT05983471)
- Testing
- ME-015 (Suplatast Tosilate)
- Where
- 6 sites in India
- Volunteers
- 40 people
- Sponsor
- Melius Pharma AB
Pulmonary Fibrosis
Roll Over Study From 1199.30 BIBF 1120 in Idiopathic Pulmonary Fibrosis (IPF)
The aim of this trial is to offer continuation of BIBF 1120 treatment for patients with Idiopathic Pulmonary Fibrosis (IPF) who have completed a prior clinical trial with that drug.
- Trial name
- NCT01170065
- Testing
- BIBF 1120
- Where
- 57 sites in Argentina, Australia and 19 more
- Volunteers
- 198 people
- Sponsor
- Boehringer Ingelheim
Pulmonary Fibroses, Idiopathic
Study to Assess CMR316 in Healthy Volunteers and Patients With Idiopathic Pulmonary Fibrosis
The purpose of this study is to assess the safety, tolerability and pharmacokinetics single and multiple inhaled doses of CMR316 in healthy volunteers and patients with Idiopathic Pulmonary Fibrosis (IPF).
- Trial name
- NCT06589219
- Testing
- CMR316
- Where
- Germany
- Volunteers
- 89 people, healthy volunteers welcome
- Sponsor
- Calibr, a division of Scripps Research
Pulmonary Fibrosis, Idiopathic
The Effect Of Baduanjin Exercises In Patients With Idiopathic Pulmonary Fibrosis
Introduction and Objectives:IPF, characterized by shortness of breath and progressive deterioration in lung function.Baduanjin (BJ) is a mindbody health exercise that combines physical exercise with psychological properties to…
- Trial name
- NCT06372353
- Testing
- Baduanjin Exercise
- Where
- Turkey (Türkiye)
- Volunteers
- 28 people
- Sponsor
- Marmara University
Pulmonary Fibrosis, Unspecified
68Ga-NOTA-PRGD2 PET/CT in Patients With Lung Injury and Pulmonary Fibrosis
This is an open-label positron emission tomography/computed tomography (PET/CT) study to investigate the diagnostic performance and evaluation efficacy of 68Ga-NOTA-PRGD2 in lung injury (LI) and pulmonary fibrosis (PF) patients.
- Trial name
- NCT02511197
- Testing
- 68Ga-NOTA-PRGD2, PET/CT
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Peking Union Medical College Hospital
Idiopathic Pulmonary Fibrosis
Minocycline Therapy for Lung Scarring in Patients With Idiopathic Pulmonary Fibrosis - a Pilot Study
Pulmonary fibrosis is essentially scarring in the lungs. Some types (DIP, NSIP) most often respond to therapy. Others like UIP (usual interstitial pneumonitis) rarely respond.
- Trial name
- NCT00203697
- Testing
- minocycline
- Where
- United States
- Sponsor
- University of California, Los Angeles
COVID-19, Pulmonary Fibrosis
Home Monitoring and Evaluation After Admission for COVID-19 in the Netherlands
To date, little is known about the short and long-term complications of COVID-19. In order to obtain more insights in disease course and recovery of COVID-19 and to improve care after hospital admission, patients with COVID-19…
- Trial name
- HOMECOMIN' (NCT04488562)
- Where
- 3 sites in Netherlands
- Volunteers
- 133 people
- Sponsor
- Erasmus Medical Center
Idiopathic Pulmonary Fibrosis
Single and Multiple Dose Safety, Tolerability, PK and Food Effect Study of HEC585 in Healthy Male and Female Subjects
The Safety, Tolerability Pharmacokinetic and Food Effect Study of HEC585 in Healthy Male and Female Subjects
- Trial name
- NCT04512170
- Testing
- HEC585
- Where
- China
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Sunshine Lake Pharma Co., Ltd.
Respiratory Tract Diseases
Evaluation and Reconditioning of Marginal Lung Donors to Transplantation by ex Vivo Lung Perfusion
Only about 15% of the potential candidates for lung donation are considered suitable for transplantation. A new method for ex vivo lung perfusion (EVLP) has been developed and can be used for evaluation and reconditioning of…
- Trial name
- NCT01353105
- Testing
- Ex vivo lung transplantation
- Where
- Brazil
- Volunteers
- 20 people
- Sponsor
- InCor Heart Institute
Idiopathic Pulmonary Fibrosis
Quality of Life in IPF - Patient and Physician Perceptions
This study aims to evaluate the differences between patient's and their physicians' perception of quality of life and the effect of disease severity and co-morbidities.
- Trial name
- QUALY-IPF-PPP (NCT04148157)
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- University of Washington
Idiopathic Pulmonary Fibrosis, Obstructive Sleep Apnea
Effect of CPAP on Abnormal Gastroesophageal Reflux and Lung Inflammation in IPF
This study will evaluate the effect of CPAP therapy on esophageal pH and lung inflammation in patients with idiopathic pulmonary fibrosis (IPF) and sleep apnea.
- Conditions
- Idiopathic Pulmonary Fibrosis, Obstructive Sleep Apnea, Gastro Esophageal Reflux
- Trial name
- NCT05359965
- Testing
- Positive Airway Pressure
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- University of Arizona
Interstitial Lung Disease with Progressive Fibrotic Phenotype in Diseases Classified Elsewhere, Systemic Sclerosis Pulmonary
Home Based Clinical Management of Interstitial Lung Disease in Systemic Rheumatic Diseases
The RMD-mILDer trial is a home monitoring strategy trial aiming to improve management of interstitial lung disease related to rheumatic diseases applying eHealth technology.
- Conditions
- Interstitial Lung Disease with Progressive Fibrotic Phenotype in Diseases Classified Elsewhere, Systemic Sclerosis Pulmonary, Dermatomyositis, Rheumatoid Arthritis
- Trial name
- RMD-mILDer (NCT06732674)
- Testing
- A home monitoring strategy with event driven management
- Where
- Norway
- Volunteers
- 218 people
- Sponsor
- Oslo University Hospital
Lung Diseases, Interstitial
An Expanded Access Program in Belgium to Provide Nintedanib to People With Lung Diseases Called Non-IPF ILDs Who Have no Alternative Treatment Options
This Expanded Access Program in Belgium is open to people with different lung diseases. This program provides a medicine called nintedanib to people who have no alternative treatment options.
- Trial name
- NCT04739150
- Testing
- nintedanib
- Where
- 14 sites in Belgium
- Sponsor
- Boehringer Ingelheim
Idiopathic Pulmonary Fibrosis, Neuromuscular Electrical Stimulation
Neuromuscular Electrical Stimulation in Patients With Idiopathic Pulmonary Fibrosis
Pulmonary rehabilitation should be initiated and lifelong at the time of diagnosis for patients with IPF. However, the symptoms of the disease and its progression limit clinical options in terms of participation and…
- Trial name
- NCT03890250
- Testing
- Aerobic exercise, Neuromuscular electrical stimulation
- Where
- Turkey (Türkiye)
- Volunteers
- 22 people
- Sponsor
- Biruni University